SCHEMBL6842856

SCHEMBL6842856

CC(=O)Nc1cc(-c2nc(-c3ccc(Cl)cc3)c(-c3ncc[nH]3)s2)ccn1

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.45
PIK3C3 Q8NEB9 5/20 0.44
MAPK14 Q16539 11/20 0.42
GSK3B P49841 2/20 0.41
NPC1 O15118 1/20 0.39
NR1I2 O75469 1/20 0.39
AHR P35869 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
ADORA3 P0DMS8 1/20 0.39
TGFBR1 P36897 1/20 0.39
TGFBR2 P37173 1/20 0.39
MAPK13 O15264 1/20 0.39
MAPK12 P53778 1/20 0.39
KCNH2 Q12809 1/20 0.39
MAPK11 Q15759 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6845075 0.91 PIK3C3 (0.45) KDM4EPIK3C3MAPK14GSK3BNPC1
SCHEMBL6842868 0.91 MAPK14 (0.47) PIK3C3MAPK14GSK3BADORA3MAPK13
SCHEMBL6842861 0.91 PIK3C3 (0.45) PIK3C3MAPK14GSK3BMAPK13MAPK12
SCHEMBL6842841 0.91 PIK3C3 (0.47) PIK3C3MAPK14GSK3BADORA3MAPK13
SCHEMBL6842818 0.91 MAPK14 (0.43) PIK3C3MAPK14GSK3B
SCHEMBL952377 0.90 MAPK14 (0.48) KDM4EPIK3C3MAPK14ADORA3MAPK13
SCHEMBL6842823 0.90 MAPK14 (0.49) KDM4EPIK3C3MAPK14GSK3BNPC1
SCHEMBL6842830 0.89 PIK3C3 (0.42) KDM4EPIK3C3MAPK14GSK3BTGFBR1
SCHEMBL16938028 0.89 MAPK14 (0.46) PIK3C3MAPK14GSK3B
SCHEMBL954402 0.89 CDC7 (0.43) PIK3C3MAPK14GSK3BTGFBR1TGFBR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9139589-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-09-22 US disclosed
US-9139589-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-09-22 US disclosed
US-9090601-B2 Thiazole derivatives MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-07-28 US disclosed
US-9090601-B2 Thiazole derivatives MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-07-28 US disclosed
US-20110003807-A1 Thiazole derivatives MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
US-20110003807-A1 Thiazole derivatives MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
US-20110003806-A1 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
US-20110003806-A1 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003807-A1 Thiazole derivatives MTOR, RICTOR, AKT2 KDM4E 1981/4885PIK3C3 15/4885MAPK14 102/4885
US-20110003806-A1 Heteroaryls and uses thereof RICTOR, MTOR, AKT1S1 KDM4E 2304/4885PIK3C3 61/4885MAPK14 899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.